Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.24
Price+2.74%
$0.22
1Y
Price
Market Cap
$475.401m
Small
Price/Earnings 3y Avg5y Avg
21.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.8%
EBITDA Margin+9.1%
Net Profit Margin-2.8%
Free Cash Flow Margin+20.8%
EBITDA Margin+9.1%
Net Profit Margin-2.8%
Free Cash Flow MarginRevenue
$181.682m
+0.7%
1y CAGR+8.6%
3y CAGR+9.0%
5y CAGREarnings
$20.366m
+0.8%
1y CAGR+38.4%
3y CAGR+143.0%
5y CAGREPS
$0.35
-5.4%
1y CAGR+36.4%
3y CAGR+127.3%
5y CAGRBook Value
$259.387m
$383.021m
Assets$123.634m
Liabilities$11.641m
DebtDebt to Assets
3.0%
0.3x
Debt to EBITDAFree Cash Flow
$16.530m
-2.4%
1y CAGR+814.8%
3y CAGR+584.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company